Post-approval studies (Phase 4)Looking for participantsNCT07564505
What this trial is testing
A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease
Who this might be right for
Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 30